Treatments > ASCO 2003 Lymphoma-Specific Abstracts

Last update: 04/20/2004

Search ASCO 

Aggressive | Antiangiogenesis | CLL | Immune-based treatments | Indolent | New / Novel | MALT / Extranodal 
Refractory | Rituxan | Survival / Side Effect / Tests | T-cell | Transplants | MISC ungrouped

Aggressive lymphomas

• A phase II-b trial of amifostine plus CHOP vs CHOP in elderly patients with aggressive non-Hodgkin's lymphoma - Abstract No: 2988 

• A phase II trial of daunoxome-substituted CHOP in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma - Abstract No: 2404 

• A prospective multicentric phase II study of the C5r regimen in 102 patients with primary cerebral lymphoma (PCNSL): A study of the Gela. - Abstract No: 2272 

• ACVBP regimen vs. CHOP in the treatment of advanced aggressive non-hodgkin's lymphoma (NHL). Results of the LNH93-5 study with a median follow-up of 5 years. - Abstract No: 2307 

• Chemotherapy alone with the ACVBP regimen is superior to three cycles of CHOP plus radiotherapy for treatment of low risk localized aggressive lymphoma: The LNH93-1 GELA study.- Abstract No: 2394 

• Cyclophosphamide/pegylated liposomal doxorubicin/vincristine/prednisone (CDOP) in the treatment of intermediate grade non-Hodgkin's lymphoma (IG-NHL): A five-year follow-up - Abstract No: 2397 

• Effects of G-CSF schedule on leukocyte recovery and infection rate in the CHOP-14 regimen for elderly patients with aggressive lymphoma - Abstract No: 2402 

• Feasibility and efficacy of dose-escalated CHOP regimen for diffuse large B-cell lymphoma (DLBCL). - Abstract No: 2407 

• High dose celecoxib and low dose cyclophosphamide for relapsed aggressive histology NHL - Abstract No: 827 

• Low risk patients with aggressive non-Hodgkin's lymphoma have superior survival with dose density chemotherapy. - Abstract No: 2306 

• Oral combination chemotherapy with Pep-C (C3) for mantle cell lymphoma (MCL): Daily prednisone, etoposide, procarbazine and cyclophosphamide - Abstract No: 2396 

• Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL) - Abstract No: 2276 

• Primary gastrointestinal diffuse large B-cell non-Hodgkin's lymphoma report of 251 cases: Institution experience - Abstract No: 2406 

• Results of the FAB international study in children and adolescents (C+A) with localised, resected B cell lymphoma (large cell [LCL], Burkitt [BL] and Burkitt-like [BLL]). - Abstract No: 3197 

• Also see Transplants | Relapsed / Refractory

Return to top

Antiangiogenesis

• Anti-VEGF receptor antibodies inhibit the growth of non-Hodgkin's lymphoma and enhance the effects of chemotherapy or rituximab in lymphoma xenograft mouse models - Abstract No: 841 

• A unique methodology using dynamic contrast enhanced MRI (DEMRI) for quantifying antiangiogenic effects (AAE) of chemotherapy: AAE of docetaxel (DOC) correlate with tumor response (TR). - Abstract No: 824 

Return to top

CLL

• Alemtuzumab for minimal residual disease in CLL - Abstract No: 2290 

• Pentostatin, cyclophosphamide and rituximab (PCR therapy): A new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL). - Abstract No: 2334 

• Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL - Abstract No: 2329 

• High efficacy and better hematological safety of reduced dose of bendamustin in extendedly pretreated patients with advanced, relapsed or refractory B-CLL: Phase I/II study of the German CLL Study Group - Abstract No: 2371 

Return to top

Immune-based Therapies / Vaccines

• A phase 1 trial of the novel DNA vaccine ZYC300 targeting the tumor specific antigen CYP1B1 in advanced malignancies - Abstract No: 679 

• Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression - Abstract No: 3424 

• Dipeptidyl peptidase inhibitor PT-100: An anti-tumor small molecule that amplifies immunity. - Abstract No: 860

• Effects of 41.8?C whole body hyperthermia (WBH) on T cell homing molecules in patients with advanced malignancies - Abstract No: 3475 

• IgA antibodies as promising new therapeutic agents for EGF- receptor directed immunotherapy - Abstract No: 691 

• Immunophenotype of CD4 and CD8 T cells from patients with B cell malignancies: Evidence for antigen-driven T cell activation - Abstract No: 3451

• Safety and efficacy of heat shock protein-peptide 96 complex (HSPPC-96) in low-grade lymphoma. - Abstract No: 2294 

• T-cell responses by tumor antigen vaccination in mantle cell lymphoma following rituximab-based treatment- Abstract No: 663 

Return to top

Indolent Lymphoma

• Stage IV indolent lymphoma: A randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance - Abstract No: 2269 

Return to top

New / Novel Agents

• A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. - Abstract No: 802 

• Bcl-2 antisense (G3139, oblimersen) and rituximab enhance chemosensitivity of EBV-associated lymphoproliferative disease in vitro and in vivo - Abstract No: 863 

• CR4, a novel protein kinase inhibitor inhibits STAT3 phosphorylation, suppresses proliferation and induces apoptosis in diffuse large B cell lymphoma cells - Abstract No: 2383 

• Interim analysis of a phase II study of denileukin diftitox (ONTAK) for B and T-cell non-Hodgkin's lymphoma - Abstract No: 2292 

• Interim results from a phase I/II study of anti-CD80 antibody (IDEC-114) therapy for follicular NHL - Abstract No: 2310 

• Flavopiridol enhances tumor response to radiotherapy - Abstract No: 3478 

• Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies - Abstract No: 722 

• Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma - Abstract No: 776 

• Phase II clinical experience with the proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent lymphomas - Abstract No: 2277 

• Treatment of Waldenstrom's macroglobulinemia with clarithromycin (BIAXIN), low dose thalidomide and dexamethasone (BLT-D) - Abstract No: 2350 

Return to top

MALT and  Extranodal Lymphomas

• Anti-apoptosis gene "survivin" in gastric MALT lymphoma patients (pts): Correlation with therapeutic response after eradication for Helicobacter pylori (HP) Abstract No: 3479 

• Early stage primary testicular lymphoma: Treatment and outcome - Abstract No: 2399 

• Evidence for association between chlamydia psittaci infection and ocular adnexal lymphoma (OAL) - Abstract No: 2273 

• Non-Hodgkin's lymphoma of the ocular adnexae; three decades of experience at a single UK centre. - Abstract No: 2403 

• Non-gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma; the treatment outcomes and patterns of failure - Abstract No: 2408 

• Oral combination chemotherapy with Pep-C (C3) for mantle cell lymphoma (MCL): Daily prednisone, etoposide, procarbazine and cyclophosphamide - Abstract No: 2396 

Return to top

Refractory / Salvage

• A 5 year follow-up of STAMP I and amifostine followed by autologous STEM cell rescue for relapsed/refractory NHL: A phase I study.- Abstract No: 3381 

• Ara-c, vm-26, cbp,dxm combination therapy for refractory and relapsed non-Hodgkin? lymphoma - Abstract No: 2444 

• Clinical experience with the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with hematological malignancies - Abstract No: 2321 

• Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma - Abstract No: 2430 

• Dhap or eshap for relapsed lymphoma. Long-term experience from a single institution - Abstract No: 2452 

• Durable remissions and minor late toxicity may be obtained in patients treated at first or second recurrence of B cell non-Hodgkin's lymphoma (NHL) with tositumomab and I 131 tositumomab. - Abstract No: 2405 

• Non-conventional ICE (IFOSFAMIDE, CARBOPLATIN AND ETOPOSIDE) for recurrent aggressive non-hodgkin lymphoma: An effective and safe outpatient regimen - Abstract No: 2463 

• Phase I trial of oral gallium maltolate in refractory malignancies - Abstract No: 943 

• Post bexxar relapse in NHL responds to zevalin and can be safely accomplished. - Abstract No: 2465 

• Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan - Abstract No: 429 

• Salvage temozolomide (TMZ) in primary brain lymphomas (PBL): A phase II trial - Abstract No: 2296 

• Yttrium-90 ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with relapsed or refractory low grade, follicular or transformed B-cell NHL: Final results of a randomized controlled trial - Abstract No: 2315 

• Also see Transplants

Return to top

Rituxan

• Bendamustine plus rituximab is highly effective in the treatment of advanced low-grade and mantle cell lymphomas with unfavorable prognosis - Abstract No: 2380 

• Rituximab maintenance for patients with low grade non-Hodgkin's lymphoma: An experience in the Northeast of Brazil. - Abstract No: 759 

• Rituximab as an alternative treatment for primary central nervous system lymphoma (PCNSL). - Abstract No: 490 

• Successful response to rituximab as a single agent in bone non-Hodgkin lymphoma - Abstract No: 758 

• The use of rituximab in 28 adults with chronic immune thrombocytopenic purpura (ITP) - Abstract No: 749 

Return to top

Survival / Side Effects / Tests / QOL

• Accuracy of end of treatment 18F-FDG PET for predicting relapse in patients with Hodgkin's disease (Hd) and non-Hodgkin's lymphoma (Nhl) - Abstract No: 2299 

• Anthracyclines during pregnancy: Factors influencing fetal outcome. - Abstract No: 3037 

• Cardiac effects of depsipeptide, FK228, in patients with T-cell lymphoma - Abstract No: 806 

• Conformal avoidance radiotherapy for Hodgkin's disease and non-Hodgkin's lymphoma: A new mantle - Abstract No: 2385 

• Ignorance of seropositivity in cancer patients: Early death in non-Hodgkin lymphoma due to reactivation of hepatitis B - Abstract No: 2388 

• Impact of weight on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation (AHCT) - Abstract No: 3342 

• Lack of treatment-related MDS/AML in patients with follicular lymphoma after frontline therapy with tositumomab and iodine I 131 tositumomab - Abstract No: 2313 

• Long-term outcome and analysis of prognostic factors for 201 patients (pt) treated with radiotherapy (RT) alone for stage I-II lymphocyte predominant Hodgkin's disease (LPHD) - Abstract No: 2300 

• Prevalence of anemia in diffuse large cell non-Hodgkin's lymphoma (DLCL). - Abstract No: 3193 

• Prognostic relevance of t(14;18) status in follicular lymphoma (FL) - Abstract No: 2319 

• Relationship of degree of bone marrow involvement with hematologic toxicity in patients with non-Hodgkin's lymphoma treated with tositumomab and iodine I 131 tositumomab. - Abstract No: 2314 

• Secondary myelodysplasia following purine analog therapy - Abstract No: 2477 

• Subcutaneous administration of amifostine during radiotherapy: A clinical perspective. - Abstract No: 3154 

• Symptom prevalence, severity, and pain management index in advanced cancer patients: The Russian experience. - Abstract No: 3142 

• The pasqoc study - patient satisfaction and quality of life in oncological care. - Abstract No: 2215 

• The role of bone marrow biopsy in non-Hodgkin's lymphoma in adult patients - Abstract No: 2436 

Return to top

T-Cell Lymphoma

• Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T cell/NK lymphoma: Preliminary results of the phase II GELA study LNH98T7 - Abstract No: 2375 

• Pilot study of recombinant human soluble tumor necrosis factor receptor (P75) fusion protein etanercept in patients with relapsed cutaneous T-cell lymphomas - Abstract No: 2374 

• Phase I clinical trial of O6benzylguanine and topical BCNU in the treatment of cutaneous T-cell lymphoma - Abstract No: 2295 

• Outcomes in cutaneous T-cell lymphoma patients treated with denileukin diftitox - Abstract No: 2376 

• Proposal of new staging system in extranodal NK/T-cell lymphoma - Abstract No: 2377 

• Standard allogeneic hematopoietic stem cell transplantation (allo-HSCT) for adult T-cell leukemia (ATL) provides long-term survival in some patients possibly by graft-versus ATL (GvATL) effect; a retrospective analysis - Abstract No: 3366 

• The efficacy of etoposide-containing regimen as the salvage therapy in extranodal NK/T cell lymphoma. - Abstract No: 2378 

Return to top

Transplants

• Allogeneic STEM cell transplantation for non-hodgkins lymphoma - Abstract No: 2462 

• Autologous transplantation with recombinant interlukin-2 activated bone marrow (ABM) for lymphoma - Abstract No: 3380 

• Autologous versus allogeneic stem cell transplantation in chronic lymphocytic leukemia - Abstract No: 3340 

• Blood and marrow transplantation for relapsed-diffuse large cell non-Hodgkin's lymphoma: An analysis of allografts vs autografts.- Abstract No: 2386 

• EPOCH-fludarabine, a novel combination chemotherapy regimen for disease control and immune depletion before reduced-intensity allogeneic stem cell transplantation - Abstract No: 3370 

• Failure pattern of aggressive non-hodgkin's lymphoma after autologous stem cell transplantation - Abstract No: 2474 

• Feasibility of reduced-intensity stem cell transplantation for patients older than 60 years with advanced hematological malignancies. - Abstract No: 3348 

• Impact of molecular (mol) HLA typing and anti-thymocyte globulin (ATG) on nonmyeloablative (NMA) unrelated donor bone marrow transplants (BMT) - Abstract No: 3360 

• Melphalan and total body irradiation (Mel-TBI) is associated with a high rate of transplant-related toxicity in allogeneic BMT - Abstract No: 3383 

• Phase II study of auto transplant with IL2 incubated PBSC and post-transplant IL 2 in relapsed NHL - Abstract No: 3373 

• Sequential myeloablative thiotepa with autologous stem cell rescue (ASCR) for patients with recurrent tumors - Abstract No: 3374 

• Use of rituximab (R) prior to peripheral blood progenitor cell mobilization does not affect mobilization kinetics. - Abstract No: 3362 

• Ten years of autologous peripheral stem cell transplantation with the same conditioning regimen (CBV) in 279 consecutive lymphoma patients done in a single center. Evaluation of prognostic factors affecting outcome. - Abstract No: 2441 

Return to top

Ungrouped

• Filgrastim experience in diverse nonmyeloid malignancies: A prospective study in community oncology practice - Abstract No: 728 

• Food and Drug Administration (FDA) experience with the accelerated approval program for oncology products - Abstract No: 2094 

• Indirect costs of cancer: Costs of absence and short-term disability in patients with seven tumor types - Abstract No: 2188 

• Quality in reporting results of phase I clinical trials of cytotoxic anticancer agents. - Abstract No: 604 

• Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage IA/IIA supra-diaphragmatic hodgkins disease (HD). Preliminary results of the UK Lymphoma Group LY07 trial. - Abstract No: 2304 

• Prevalence of anemia in an oncology practice: A retrospective review - Abstract No: 3181 

• Residential exposure to electric power transmission lines in childhood increases the risk of myeloproliferative and lymphoproliferative disorders in later life. - Abstract No: 3602 

Return to top